Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1002 (Trichuris suis ova) for Crohn's disease
ACTRN12608000241336Phase 2Not yet recruiting
- Sponsor
- Asphelia Pharmaceuticals, Inc.
- Start
- Jun 2008
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing ASP1002 with Placebo (2 arms). Primary endpoints: Clinical response at Week 12, Durability of remission to Week 24 and 1 more. Planned start Jun 2008; status: not yet recruiting.
02
Drugs
ASP1002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ACTRN12608000241336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000241336.